Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
If you are considering the GeneSight pharmacogenomic test to guide your mental health treatment, the decision is no longer just about the science; it is about navigating a complex 2026 landscape of ...
YORK, Pa. — A simple cheek swab claims to give patients an individualized look at which medications are best suited for their mental health, based on their DNA. "There may be an issue where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results